세계의 도파민 작용제 시장 : 시장 규모의 분석 및 예측 - 투여 경로별, 용도별, 유통 채널별, 지역별(2022-2032년)

The Global Dopamine Agonist Market is valued at approximately USD 1.24 billion in 2023 and is anticipated to expand at a steady CAGR of 5.70% over the forecast period 2024-2032. Dopamine agonists are pivotal in the treatment of neurological disorders such as Parkinson's disease and restless leg syndrome, playing a crucial role in modulating dopamine levels in the brain to improve motor function. With increasing global incidences of neurodegenerative conditions, the demand for dopamine agonists continues to rise. Additionally, continuous advancements in drug formulations and the development of novel, extended-release medications contribute to market expansion, ensuring improved patient compliance and therapeutic outcomes.

Moreover, pharmaceutical companies are investing heavily in research and development to enhance drug efficacy while minimizing side effects. The shift towards non-ergot dopamine agonists, which have fewer adverse effects than ergot derivatives, has gained significant traction. This transition is particularly crucial for long-term treatments, as newer drugs demonstrate improved safety profiles. Additionally, the growing aging population, particularly in developed regions, has further spurred demand, as Parkinson's disease and related movement disorders become more prevalent with age. However, the high cost of dopamine agonists and the potential side effects associated with long-term usage may hinder market growth in certain regions.

The North American market dominates the global dopamine agonist industry due to well-established healthcare infrastructure, high awareness levels, and the presence of major pharmaceutical companies. The United States, in particular, remains a stronghold due to its significant investments in neurology-focused drug development. Meanwhile, Europe follows closely, driven by increasing government initiatives and funding for neurodegenerative disease research. The Asia Pacific region is poised to witness the fastest growth over the forecast period, spurred by rising healthcare expenditure, increasing diagnoses of neurological disorders, and expanding access to advanced treatment options. Countries such as China and India are seeing a surge in demand due to improving healthcare systems and heightened awareness regarding movement disorders.

Major Market Players Included in This Report Are:

• AbbVie Inc.
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Novartis AG
• UCB S.A.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals, Inc.
• Acadia Pharmaceuticals Inc.
• Zambon S.p.A.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories Ltd.

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Drug:

• Non-ergot Dopamine Agonists
• Ergot Alkaloids

By Route of Administration:

• Oral
• Injectable

By Application:

• Parkinson's Disease
• Restless Leg Syndrome
• Hyperprolactinemia
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific:

• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America:

• Brazil
• Mexico

Middle East & Africa:

• Saudi Arabia
• South Africa
• Rest of MEA

Years Considered for the Study:

• Historical Year - 2022, 2023
• Base Year - 2023
• Forecast Period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecasts for 10 years (2022-2032)
• Annualized revenues and regional-level analysis for each market segment
• Comprehensive geographical assessment, including country-level breakdowns
• Competitive landscape with strategic insights into key players
• Detailed evaluation of business strategies and market positioning
• In-depth demand and supply chain analysis for a 360-degree industry perspective

Table of Contents

Chapter 1. Global Dopamine Agonist Market Executive Summary

• 1.1. Global Dopamine Agonist Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug
    • Non-ergot Dopamine Agonists
    • Ergot Alkaloids
  • 1.3.2. By Route of Administration
    • Oral
    • Injectable
  • 1.3.3. By Application
    • Parkinson's Disease
    • Restless Leg Syndrome
    • Hyperprolactinemia
    • Others
  • 1.3.4. By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Dopamine Agonist Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Dopamine Agonist Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Incidence of Neurological Disorders
  • 3.1.2. Advancements in Drug Formulations and Extended-release Technologies
  • 3.1.3. Enhanced Investment in Pharmaceutical R&D
• 3.2. Market Challenges
  • 3.2.1. High Cost of Dopamine Agonists
  • 3.2.2. Adverse Side Effects and Long-term Safety Concerns
• 3.3. Market Opportunities
  • 3.3.1. Expanding Demand in Aging Populations
  • 3.3.2. Opportunities in Emerging Markets
  • 3.3.3. Innovation in Drug Delivery Systems

Chapter 4. Global Dopamine Agonist Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Dopamine Agonist Market Size & Forecasts by Drug 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Dopamine Agonist Market: Drug Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.2.1. Non-ergot Dopamine Agonists
  • 5.2.2. Ergot Alkaloids

Chapter 6. Global Dopamine Agonist Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Dopamine Agonist Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 6.2.1. Oral
  • 6.2.2. Injectable

Chapter 7. Global Dopamine Agonist Market Size & Forecasts by Application 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Dopamine Agonist Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 7.2.1. Parkinson's Disease
  • 7.2.2. Restless Leg Syndrome
  • 7.2.3. Hyperprolactinemia
  • 7.2.4. Others

Chapter 8. Global Dopamine Agonist Market Size & Forecasts by Distribution Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Dopamine Agonist Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies

Chapter 9. Global Dopamine Agonist Market Size & Forecasts by Region 2022-2032

• 9.1. North America Dopamine Agonist Market
  • 9.1.1. U.S. Dopamine Agonist Market
    • 9.1.1.1. Drug Breakdown Size & Forecasts, 2022-2032
    • 9.1.1.2. Route of Administration Breakdown Size & Forecasts, 2022-2032
  • 9.1.2. Canada Dopamine Agonist Market
• 9.2. Europe Dopamine Agonist Market
  • 9.2.1. U.K. Dopamine Agonist Market
  • 9.2.2. Germany Dopamine Agonist Market
  • 9.2.3. France Dopamine Agonist Market
  • 9.2.4. Spain Dopamine Agonist Market
  • 9.2.5. Italy Dopamine Agonist Market
  • 9.2.6. Rest of Europe Dopamine Agonist Market
• 9.3. Asia Pacific Dopamine Agonist Market
  • 9.3.1. China Dopamine Agonist Market
  • 9.3.2. India Dopamine Agonist Market
  • 9.3.3. Japan Dopamine Agonist Market
  • 9.3.4. Australia Dopamine Agonist Market
  • 9.3.5. South Korea Dopamine Agonist Market
  • 9.3.6. Rest of Asia Pacific Dopamine Agonist Market
• 9.4. Latin America Dopamine Agonist Market
  • 9.4.1. Brazil Dopamine Agonist Market
  • 9.4.2. Mexico Dopamine Agonist Market
  • 9.4.3. Rest of Latin America Dopamine Agonist Market
• 9.5. Middle East & Africa Dopamine Agonist Market
  • 9.5.1. Saudi Arabia Dopamine Agonist Market
  • 9.5.2. South Africa Dopamine Agonist Market
  • 9.5.3. Rest of Middle East & Africa Dopamine Agonist Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. AbbVie Inc.
  • 10.1.2. GlaxoSmithKline plc
  • 10.1.3. Boehringer Ingelheim International GmbH
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. AbbVie Inc.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Pfizer Inc.
  • 10.3.3. Novartis AG
  • 10.3.4. UCB S.A.
  • 10.3.5. Teva Pharmaceutical Industries Ltd.
  • 10.3.6. Sun Pharmaceutical Industries Ltd.
  • 10.3.7. Amneal Pharmaceuticals, Inc.
  • 10.3.8. Acadia Pharmaceuticals Inc.
  • 10.3.9. Zambon S.p.A.
  • 10.3.10. Cipla Inc.
  • 10.3.11. Hikma Pharmaceuticals PLC
  • 10.3.12. Bausch Health Companies Inc.
  • 10.3.13. Dr. Reddy's Laboratories Ltd.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes